Rubius Therapeutics
OverviewSuggest Edit
Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
| Type | Public | |
| Founded | 2013 | |
| HQ | Cambridge, MA, US | Map |
| Website | rubiustx.com |
Recent NewsAll News
- Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
- Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
- Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
- Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Key People/Management at Rubius Therapeutics
Pablo J. Cagnoni
Chief Executive Officer, Director
Christina Coughlin
Chief Medical Officer
Andrew Oh
Chief Financial Officer
Kris Elverum
Senior Vice President, Business Development and Strategy
Spencer Fisk
Senior Vice President & Chief Technical Operations Officer
Bryan Gillis
Vice President, Manufacturing
Rubius Therapeutics Office Locations
Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, MA, US (HQ)
399 Binney St #300
Smithfield, RI, US
100 Technology Way
Rubius Therapeutics Financials and Metrics
Rubius Therapeutics Revenue
| USD | |
|---|---|
Net income (Q1, 2021) | (42.3m) |
EBIT (Q1, 2021) | (40.9m) |
Market capitalization (30-Jul-2021) | 1.9b |
Closing stock price (30-Jul-2021) | 21.5 |
Cash (31-Mar-2021) | 288.1m |
EV | 1.7b |
Rubius Therapeutics's current market capitalization is $1.9 b.
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.1m | 5.8m | 16.3m | 13.2m | 13.5m | 13.8m | 15.0m | 12.7m | 11.6m | 13.2m |
R&D expense | 3.7m | 9.7m | 12.0m | 14.4m | 20.9m | 27.5m | 33.5m | 36.2m | 26.1m | 27.7m |
Operating expense total | 4.8m | 15.4m | 28.2m | 27.6m | 34.4m | 41.3m | 48.5m | 48.9m | 37.7m | 40.9m |
EBIT | (4.8m) | (15.4m) | (28.2m) | (27.6m) | (34.4m) | (41.3m) | (48.5m) | (48.8m) | (37.7m) | (40.9m) |
Annual
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.9m) | (15.3m) | (44.4m) | (62.0m) | (32.6m) | (72.0m) | (119.0m) | (42.3m) | ||
Depreciation and Amortization | 48.0k | 227.0k | 502.0k | 879.0k | 661.0k | 1.4m | 2.3m | 1.8m | 3.6m | 1.5m |
Accounts Payable | 937.0k | 452.0k | 3.0m | 2.4m | (966.0k) | (4.7m) | 3.2m | 905.0k | 3.1m | (757.0k) |
Cash From Operating Activities | (3.1m) | (10.9m) | (20.8m) | (38.6m) | (22.9m) | (52.7m) | (81.5m) | (40.0m) | (68.6m) | (38.7m) |
| USD | FY, 2016 |
|---|---|
Debt/Equity | 6.3 x |
Debt/Assets | 1.5 x |
Financial Leverage | 4.1 x |
Rubius Therapeutics Cybersecurity Score
Rubius Therapeutics Environment, Social & Governance (ESG) Ratings
Rubius Therapeutics Online and Social Media Presence
1.32k Twitter followers
Rubius Therapeutics has 1.32k Twitter Followers. The number of followers has increased 1.6% month over month and increased 4.2% quarter over quarter
Rubius Therapeutics's Trends
Twitter Engagement Stats for @rubius_tx
412
Tweets
280
Following
1.3k
Followers
11
Tweets last 30 days
2.5
Avg. likes per Tweet
72.7%
Tweets with engagement
Rubius Therapeutics News and Updates
July 29, 2021
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer an…
July 22, 2021
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer a…
July 15, 2021
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy
Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody
June 23, 2021
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the firs…
May 20, 2021
Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.…
May 19, 2021
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Compa…
Rubius Therapeutics Blogs
June 04, 2021
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
The post A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers appeared first on Rubius Therapeutics.
April 10, 2021
A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors
The post A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors appeared first on Rubius Therapeutics.
January 04, 2021
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Content Import
Mon, 01/04/2021 - 16:01
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
This release is a bac…
November 30, 2020
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J.
November 20, 2020
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 5 Best Places to Work in Rhode Island by Providence Business News
Brian.Hoenig@n…
Fri, 11/20/2020 - 09:27
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by…
November 10, 2020
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Content Import
Tue, 11/10/2020 - 16:02
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
November 10, 2020
This release is a backfill from a…
Rubius Therapeutics Frequently Asked Questions
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2013.
Who are Rubius Therapeutics key executives?
Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.
How many employees does Rubius Therapeutics have?
Rubius Therapeutics has 174 employees.
Who are Rubius Therapeutics competitors?
Competitors of Rubius Therapeutics include ImCheck Therapeutics, Confo Therapeutics and Sigilon.
Where is Rubius Therapeutics headquarters?
Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.
Where are Rubius Therapeutics offices?
Rubius Therapeutics has offices in Cambridge and Smithfield.
How many offices does Rubius Therapeutics have?
Rubius Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies